Bianca Pollo

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5040109/bianca-pollo-publications-by-year.pdf
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

193 papers	22,712 citations	69 h-index	150 g-index
210 ext. papers	31,432 ext. citations	8.6 avg, IF	5.41 L-index

#	Paper	IF	Citations
193	Pathological Classification of Brain Tumors **2021**, 75-105		1
192	Correlation Between Immunohistochemistry and Sequencing in H3G34-Mutant Gliomas. *American Journal of Surgical Pathology*, **2021**, 45, 200-204	6.7	4
191	Loss of H3K27me3 in meningiomas. *Neuro-Oncology*, **2021**, 23, 1282-1291	1	7
190	ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. *Cell Reports*, **2021**, 36, 109455	10.6	2
189	Peri-operative prognostic factors for primary skull base chordomas: results from a single-center cohort. *Acta Neurochirurgica*, **2021**, 163, 689-697	3	1
188	High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient. *Cancer Immunology, Immunotherapy*, **2021**, 70, 831-842	7.4	8
187	Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up. *Neuro-Oncology*, **2021**, 23, 848-857	1	7
186	LSD1-directed therapy affects glioblastoma tumorigenicity by deregulating the protective ATF4-dependent integrated stress response. *Science Translational Medicine*, **2021**, 13, eabf7036	17.5	2
185	Deciphering the Labyrinthine System of the Immune Microenvironment in Recurrent Glioblastoma: Recent Original Advances and Lessons from Clinical Immunotherapeutic Approaches.. *Cancers*, **2021**, 13,	6.6	3
184	Fluorescein-Assisted Confocal Laser Endomicroscopy (CONVIVO System) in Patients With Glioblastoma: Results From a Prospective Study. *Frontiers in Oncology*, **2020**, 10, 606574	5.3	7
183	Gliomatosis cerebri (GC) or GC-like? A picture to be reconsidered in neuro-oncology based on large retrospective analysis of GC series. *Neurological Sciences*, **2020**, 41, 2111-2120	3.5	1
182	Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersociety (SINch/AINO/SIN) document. *Journal of Neurosurgical Sciences*, **2020**, 64, 313-334	1.3	11
181	EPEN-03. LONG-TERM FOLLOW-UP OF AIEOP 2ND SERIES OF CHILDREN AND ADOLESCENT WITH PRIMARY INTRACRANIAL (ST:SUPRATENTORIAL; PF: POSTERIOR FOSSA) EPENDYMOMA AND METHYLATION GROUPS RE-ANALYSES. *Neuro-Oncology*, **2020**, 22, iii308-iii308	1	78
180	In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting. *Neurological Sciences*, **2020**, 41, 347-355	3.5	7
179	CTIM-24. AUTOLOGOUS CD34+ ENRICHED HEMATOPOIETIC PROGENITOR CELLS GENETICALLY MODIFIED FOR HUMAN INTERFERON-β, ARE WELL TOLERATED & RAPIDLY ENGRAFT IN PATIENTS WITH GLIOBLASTOMA MULTIFORME (TEM-GBM_001 STUDY). *Neuro-Oncology*, **2020**, 22, ii38-ii38	1	1
178	Sleeve-Shaped Neurothekeoma of the Ulnar Nerve: A Unique Case of a Still Unclear Pathological Entity. *Hand*, **2020**, 15, NP7-NP10	1.4	1
177	B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. *EBioMedicine*, **2019**, 47, 33-43	8.8	45

176	Long and Very-Long-Chain Ceramides Correlate with A More Aggressive Behavior in Skull Base Chordoma Patients. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	7
175	Advances in multidisciplinary therapy for meningiomas. *Neuro-Oncology*, **2019**, 21, i18-i31	1	44
174	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. *Neuro-Oncology*, **2019**, 21, 901-910	1	79
173	Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood. *Journal of Neuro-Oncology*, **2019**, 142, 435-444	4.8	10
172	Microfragmented human fat tissue is a natural scaffold for drug delivery: Potential application in cancer chemotherapy. *Journal of Controlled Release*, **2019**, 302, 2-18	11.7	17
171	The □radio-guided surgery: Method to estimate the minimum injectable activity from ex-vivo test. *Physica Medica*, **2019**, 58, 114-120	2.7	8
170	5-ALA Fluorescence in Case of Brain Abscess by Aggregatibacter Mimicking Glioblastoma. *World Neurosurgery*, **2019**, 125, 175-178	2.1	4
169	Radio-Guided Surgery with □Radiation: Tests on Ex-Vivo Specimens. *IFMBE Proceedings*, **2019**, 693-697	0.2	1
168	P05.02 A phase I/IIa dose escalation study evaluating the safety and efficacy of autologous CD34+ enriched hematopoietic progenitor cells genetically modified for human interferon-□ in patients with GBM and an unmethylated MGMT promoter (TEM-GBM-001). *Neuro-Oncology*, **2019**, 21, iii34-iii34	1	78
167	Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy. *Neuro-Oncology Advances*, **2019**, 1, vdz022	0.9	8
166	P09.03 Array-CGH analysis in meningiomas adds further information of biological behavior. *Neuro-Oncology*, **2019**, 21, iii39-iii39	1	78
165	Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. *Acta Neuropathologica*, **2019**, 137, 837-846	14.3	28
164	MNGI-07. TRIMETHYLATED H3K27 AND EZH2 EXPRESSION IN MENINGIOMA: CORRELATION WITH TENDENCY TO RECUR. *Neuro-Oncology*, **2019**, 21, vi140-vi140	1	78
163	ATIM-36. TEM-GBM-001 STUDY: AUTOLOGOUS CD34+ ENRICHED HEMATOPOIETIC PROGENITOR CELLS GENETICALLY MODIFIED FOR HUMAN INTERFERON-□ & ADMINISTERED TO PATIENTS WITH GLIOBLASTOMA & AN UNMETHYLATED MGMT PROMOTER. *Neuro-Oncology*, **2019**, 21, vi9-vi9	1	78
162	P14.64 Primary Central Nervous System Lymphoma (PCNSL) with HD- MTX based chemotherapy: tolerability and results. *Neuro-Oncology*, **2019**, 21, iii82-iii82	1	78
161	P14.74 Remarkable response to Combined BRAF and MEK Inhibitors in two Adults with leptomeningeal carcinomatosis secondary to Pleomorphic Xantoastrocytoma grade II with BRAFv600E mutation. *Neuro-Oncology*, **2019**, 21, iii85-iii85	1	78
160	Altered function of the glutamate-aspartate transporter GLAST, a potential therapeutic target in glioblastoma. *International Journal of Cancer*, **2019**, 144, 2539-2554	7.5	13
159	Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life. *Neuro-Oncology*, **2019**, 21, i32-i43	1	33

158	Imaging and diagnostic advances for intracranial meningiomas. *Neuro-Oncology*, **2019**, 21, i44-i61	1	55
157	Molecular and translational advances in meningiomas. *Neuro-Oncology*, **2019**, 21, i4-i17	1	46
156	Role of Immunohistochemistry in the Identification of Supratentorial C11ORF95-RELA Fused Ependymoma in Routine Neuropathology. *American Journal of Surgical Pathology*, **2019**, 43, 56-63	6.7	39
155	Constitutive and TNF□nducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. *Science Translational Medicine*, **2018**, 10,	17.5	67
154	Unique combination of myxopapillary ependymoma and conus lipoma with subcutaneous extension in an 11-month-old child. *Childrs Nervous System*, **2018**, 34, 597-599	1.7	
153	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. *Cell*, **2018**, 173, 400-416.e11	56.2	1072
152	Comprehensive Characterization of Cancer Driver Genes and Mutations. *Cell*, **2018**, 173, 371-385.e18	56.2	854
151	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. *Cell*, **2018**, 173, 291-304.e6	56.2	888
150	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. *Cell*, **2018**, 173, 386-399.e12	56.2	133
149	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. *Cell*, **2018**, 173, 305-320.e10	56.2	166
148	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. *Cell*, **2018**, 173, 338-354.e15	56.2	560
147	Oncogenic Signaling Pathways in The Cancer Genome Atlas. *Cell*, **2018**, 173, 321-337.e10	56.2	1124
146	Pathogenic Germline Variants in 10,389 Adult Cancers. *Cell*, **2018**, 173, 355-370.e14	56.2	342
145	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. *Cell Reports*, **2018**, 23, 282-296.e4	10.6	188
144	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. *Cell Reports*, **2018**, 23, 227-238.e3	10.6	235
143	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. *Cell Reports*, **2018**, 23, 194-212.e6	10.6	146
142	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. *Cell Reports*, **2018**, 23, 297-312.e12	10.6	147
141	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. *Cell Reports*, **2018**, 23, 313-326.e5	10.6	295

140	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. *Cell Reports*, **2018**, 23, 181-193.e7	10.6	366
139	The Immune Landscape of Cancer. *Immunity*, **2018**, 48, 812-830.e14	32.3	1754
138	Extensive and systematic rewiring of histone post-translational modifications in cancer model systems. *Nucleic Acids Research*, **2018**, 46, 3817-3832	20.1	25
137	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. *Cell Reports*, **2018**, 23, 172-180.e3	10.6	66
136	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. *Cell Reports*, **2018**, 23, 213-226.e3	10.6	56
135	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. *Cell Reports*, **2018**, 23, 239-254.e6	10.6	405
134	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. *Cell Reports*, **2018**, 23, 255-269.e4	10.6	112
133	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. *Cell Reports*, **2018**, 23, 270-281.e3	10.6	121
132	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. *Cell Systems*, **2018**, 6, 271-281.e7	10.6	320
131	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. *Cell Systems*, **2018**, 6, 282-300.e2	10.6	159
130	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. *Cancer Cell*, **2018**, 33, 706-720.e9	24.3	275
129	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. *Cancer Cell*, **2018**, 33, 676-689.e3	24.3	377
128	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. *Cancer Cell*, **2018**, 33, 721-735.e8	24.3	228
127	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. *Cancer Cell*, **2018**, 33, 690-705.e9	24.3	277
126	Fluorescein-Guided Surgery for Resection of High-Grade Gliomas: A Multicentric Prospective Phase II Study (FLUOGLIO). *Clinical Cancer Research*, **2018**, 24, 52-61	12.9	96
125	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. *Cancer Cell*, **2018**, 34, 211-224.e6	24.3	327
124	Microglia immunophenotyping in gliomas. *Oncology Letters*, **2018**, 15, 998-1006	2.6	29
123	Tetanus toxoid pre-conditioning in recurrent glioblastoma treated with dendritic cell immunotherapy is associated to CD8+ T cell response.. *Journal of Clinical Oncology*, **2018**, 36, e14053-e14053	2.3	

122	Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8 T cell activation in the presence of adjuvant temozolomide. *OncoImmunology*, **2018**, 7, e1412901	7.2	34
121	Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease. *Journal of Neurology*, **2018**, 265, 273-284	5.5	12
120	PATH-31. GIANT CELL GLIOBLASTOMAS: ANALYSIS OF MISMATCH-REPAIR (MMR) PROTEINS EXPRESSION, POLIMERASE (POLE) MUTATIONS AND THEIR ROLE IN TUMOR IMMUNORESPONSE. *Neuro-Oncology*, **2018**, 20, vi165-vi165	1	1
119	Neuro-Behçet disease presenting as an isolated progressive cognitive and behavioral syndrome. *Neurocase*, **2018**, 24, 238-241	0.8	1
118	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- Superfamily. *Cell Systems*, **2018**, 7, 422-437.e7	10.6	85
117	Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. *Cell Reports*, **2018**, 25, 1304-1317.e5	10.6	152
116	P16.14 Treatment of thalamic glial lesions: surgery versus biopsy. *Neuro-Oncology*, **2017**, 19, iii112-iii112	1	78
115	Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis. *Quantitative Imaging in Medicine and Surgery*, **2017**, 7, 592-597	3.6	3
114	Mutations targeting the coagulation pathway are enriched in brain metastases. *Scientific Reports*, **2017**, 7, 6573	4.9	6
113	P03.13 Molecular and clinical bio-markers in a series of 48 consecutive skull base chordoma patients. *Neuro-Oncology*, **2017**, 19, iii36-iii36	1	78
112	Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival. *Journal of Neuro-Oncology*, **2016**, 126, 279-88	4.8	29
111	Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model. *Journal of Experimental and Clinical Cancer Research*, **2016**, 35, 55	12.8	59
110	Tumor-initiating cell frequency is relevant for glioblastoma aggressiveness. *Oncotarget*, **2016**, 7, 71491-71503	5.5	9
109	Association of increased survival in glioblastoma patients treated with dendritic cell vaccinations and temozolomide with increased activity of NK cells and ABCC3 expression.. *Journal of Clinical Oncology*, **2016**, 34, 2039-2039	2.2	
108	HG-56HISTONE K27M MUTATION IN A SERIES OF CENTRALLY REVIEWED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG): CONSISTENCY WITH MRI FEATURES. *Neuro-Oncology*, **2016**, 18, iii60.3-iii60	1	78
107	HG-11BRAF V600E MUTATION IN PEDIATRIC ASTROBLASTOMAS. *Neuro-Oncology*, **2016**, 18, iii50.1-iii50	1	78
106	MPTH-42. NEUROPATHOLOGICAL AND MOLECULAR CHARACTERIZATION OF LONG-TERM SURVIVAL GLIOBLASTOMAS (LS-GBM): A STUDY ON 52 CASES. *Neuro-Oncology*, **2016**, 18, vi115-vi115	1	
105	A case of medulloblastoma in adult patient affected by anaplastic oligoastrocytoma. *Neurological Sciences*, **2016**, 37, 1727-30	3.5	1

104	Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. *Neuro-Oncology*, **2016**, 18, 1451-60	1	68
103	Identification of residual tumor with intraoperative contrast-enhanced ultrasound during glioblastoma resection. *Neurosurgical Focus*, **2016**, 40, E7	4.2	72
102	First ex vivo validation of a radioguided surgery technique with □radiation. *Physica Medica*, **2016**, 32, 1139-44	2.7	24
101	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *New England Journal of Medicine*, **2015**, 372, 2481-98	59.2	1828
100	Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. *Acta Neuropathologica Communications*, **2015**, 3, 4	7.3	73
99	Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials. *Journal of Clinical Oncology*, **2015**, 33, 1943-50	2.2	13
98	MPTH-28STUDY OF THE ROLE OF IFI-16 EXPRESSION IN GLIOMAS. *Neuro-Oncology*, **2015**, 17, v144.3-v144	1	78
97	Primary central nervous system angiosarcoma: a case report and literature review. *Neuropathology*, **2015**, 35, 184-91	2	13
96	IMCT-06SURVIVAL GAIN AND IMMUNE RESPONSE IN GLIOBLASTOMA PATIENTS TREATED WITH DENDRITIC CELL IMMUNOTHERAPY BEFORE AND DURING ADJUVANT TEMOZOLOMIDE. *Neuro-Oncology*, **2015**, 17, v108.2-v108	1	78
95	Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. *Journal of Neuro-Oncology*, **2014**, 118, 305-312	4.8	44
94	Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010. *Neuro-Oncology*, **2014**, 16, 719-27	1	53
93	Neuritis ossificans. *Journal of Neurosurgery*, **2014**, 121, 1287-8	3.2	2
92	P12. Combination of radiotherapy and chemotherapy with dendritic cell immunotherapy in glioblastoma patients induces NK and NKT cell responses **2014**, 2,		78
91	Involvement of the CXCL12/CXCR4/CXCR7 Axis in Brain Metastases **2014**, 25-36		1
90	Is fluorescein-guided technique able to help in resection of high-grade gliomas?. *Neurosurgical Focus*, **2014**, 36, E5	4.2	106
89	Results of nimotuzumab and vinorelbine, radiation, and re-irradiation for diffuse pontine glioma in childhood.. *Journal of Clinical Oncology*, **2014**, 32, 10020-10020	2.2	0
88	Histological variants of medulloblastoma are the most powerful clinical prognostic indicators. *Pediatric Blood and Cancer*, **2013**, 60, 210-6	3	25
87	Case report: long-term survival of an infant syndromic patient affected by atypical teratoid-rhabdoid tumor. *BMC Cancer*, **2013**, 13, 100	4.8	10

86	Fluorescein-guided surgery for grade IV gliomas with a dedicated filter on the surgical microscope: preliminary results in 12 cases. *Acta Neurochirurgica*, **2013**, 155, 1277-86	3	100
85	The somatic genomic landscape of glioblastoma. *Cell*, **2013**, 155, 462-77	56.2	2900
84	Liposomal cytarabine in neoplastic meningitis from primary brain tumors: a single institutional experience. *Neurological Sciences*, **2013**, 34, 2151-7	3.5	9
83	Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres. *Molecular Cancer*, **2013**, 12, 160	42.1	10
82	Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. *Journal of Neurosurgery* , **2013**, 118, 821-9	3.2	25
81	The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. *OncoImmunology*, **2013**, 2, e23401	7.2	42
80	Preoperative embolization of carotid chemodectoma: a technical challenge that can be customized according to angioarchitecture. Illustrative cases. *Neuroradiology Journal*, **2013**, 26, 678-82	2	5
79	Expression profile of frizzled receptors in human medulloblastomas. *Journal of Neuro-Oncology*, **2012**, 106, 271-80	4.8	10
78	Adult medulloblastoma: multiagent chemotherapy with cisplatinum and etoposide: a single institutional experience. *Journal of Neuro-Oncology*, **2012**, 106, 595-600	4.8	17
77	Multidrug resistance proteins expression in glioma patients with epilepsy. *Journal of Neuro-Oncology*, **2012**, 110, 129-35	4.8	26
76	Long-term results of combined preradiation chemotherapy and age-tailored radiotherapy doses for childhood medulloblastoma. *Journal of Neuro-Oncology*, **2012**, 108, 163-71	4.8	15
75	The MET oncogene is a functional marker of a glioblastoma stem cell subtype. *Cancer Research*, **2012**, 72, 4537-50	10.1	104
74	FABP4 is a candidate marker of cerebellar liponeurocytomas. *Journal of Neuro-Oncology*, **2012**, 108, 513-2	4.8	23
73	An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma. *PLoS ONE*, **2012**, 7, e52301	3.7	27
72	Expression of the new CXCL12 receptor, CXCR7, in gliomas. *Cancer Biology and Therapy*, **2011**, 11, 242-53	4.6	38
71	Spinal cord stimulation for recurrent painful neuromas of the foot. *Neurological Sciences*, **2011**, 32, 723-5	3.5	3
70	Neuropathological diagnosis of brain tumours. *Neurological Sciences*, **2011**, 32 Suppl 2, S209-11	3.5	18
69	DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence. *Oncologist*, **2011**, 16, 1440-50	5.7	19

68	Expression of vascular endothelial growth factor receptor-1/-2 and nitric oxide in unruptured intracranial aneurysms. *Neurological Sciences*, **2010**, 31, 617-23	3.5	4
67	CXCL12, CXCR4 and CXCR7 expression in brain metastases. *Cancer Biology and Therapy*, **2009**, 8, 1608-14	4.6	69
66	Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. *Journal of Clinical Oncology*, **2009**, 27, 566-71	2.2	110
65	Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels. *Journal of Neuro-Oncology*, **2009**, 93, 319-24	4.8	52
64	Epilepsy in cerebral glioma: timing of appearance and histological correlations. *Journal of Neuro-Oncology*, **2009**, 93, 395-400	4.8	69
63	Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. *Oncogene*, **2009**, 28, 1807-11	9.2	158
62	Aquaporin-4 contributes to the resolution of peritumoural brain oedema in human glioblastoma multiforme after combined chemotherapy and radiotherapy. *European Journal of Cancer*, **2009**, 45, 3315-25	7.5	37
61	Radiation-induced glioblastoma in a medulloblastoma patient: a case report with molecular features. *Neuropathology*, **2008**, 28, 633-9	2	16
60	A case of pediatric tumefactive demyelinating lesion misdiagnosed and treated as glioblastoma. *Journal of Child Neurology*, **2008**, 23, 944-7	2.5	20
59	Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. *Neuro-Oncology*, **2008**, 10, 79-87	1	136
58	Mucinous low-grade adenocarcinoma arising in an intracranial enterogenous cyst: case report. *Neurosurgery*, **2008**, 62, E972-3; discussion E973	3.2	21
57	Intracerebral haemorrhage in primary and metastatic brain tumours. *Neurological Sciences*, **2008**, 29 Suppl 2, S264-5	3.5	9
56	Late-onset sporadic ataxia, pontine lesion, and retroperitoneal fibrosis: a case of Erdheim-Chester disease. *Neurological Sciences*, **2008**, 29, 263-7	3.5	16
55	Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience. *Journal of Neuro-Oncology*, **2007**, 82, 273-9	4.8	15
54	Loss of heterozygosity studies in extracranial metastatic meningiomas. *Journal of Neuro-Oncology*, **2007**, 85, 81-5	4.8	12
53	Expression of cannabinoid receptors and neurotrophins in human gliomas. *Neurological Sciences*, **2007**, 28, 304-10	3.5	32
52	Expression of the neurogenic basic helix-loop-helix transcription factor NEUROG1 identifies a subgroup of medulloblastomas not expressing ATOH1. *Neuro-Oncology*, **2007**, 9, 298-307	1	28
51	Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. *Clinical Cancer Research*, **2007**, 13, 2606-13	12.9	123

50	Nestin, PDGFRbeta, CXCL12 and VEGF in glioma patients: different profiles of (pro-angiogenic) molecule expression are related with tumor grade and may provide prognostic information. *Cancer Biology and Therapy*, **2007**, 6, 1018-24	4.6	44
49	Reclassification of oligoastrocytomas by loss of heterozygosity studies. *International Journal of Cancer*, **2006**, 119, 84-90	7.5	39
48	Molecular markers of gliomas: a clinical approach. *Neurological Research*, **2006**, 28, 538-41	2.7	4
47	Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas. *Cancer Biology and Therapy*, **2006**, 5, 827-32	4.6	28
46	Production and post-surgical modification of VEGF, tPA and PAI-1 in patients with glioma. *Cancer Biology and Therapy*, **2006**, 5, 204-9	4.6	6
45	Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines. *Oncogene*, **2006**, 25, 1571-83	9.2	85
44	Meningitis following relapsing painful ophthalmoplegia in aspergillus sphenoidal sinusitis: a case report. *Neurological Sciences*, **2006**, 27, 284-7	3.5	10
43	Anaplasia is rare and does not influence prognosis in adult medulloblastoma. *Journal of Neuropathology and Experimental Neurology*, **2005**, 64, 869-74	3.1	17
42	Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. *Journal of Neuro-Oncology*, **2005**, 74, 113-21	4.8	171
41	CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients. *Journal of Neuro-Oncology*, **2005**, 74, 287-93	4.8	47
40	hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. *British Journal of Cancer*, **2005**, 93, 781-92	8.7	106
39	Neuromyelitis optica in a child with atypical onset and severe outcome. *Neuropediatrics*, **2004**, 35, 198-201	1.6	3
38	L-2-hydroxyglutaric aciduria and brain malignant tumors: a predisposing condition?. *Neurology*, **2004**, 62, 1882-4	6.5	91
37	CXCL12 in malignant glial tumors: a possible role in angiogenesis and cross-talk between endothelial and tumoral cells. *Journal of Neuro-Oncology*, **2004**, 67, 305-17	4.8	60
36	Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. *International Journal of Radiation Oncology Biology Physics*, **2004**, 58, 1336-45	4	81
35	Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma. *Molecular Cancer*, **2004**, 3, 25	42.1	53
34	Expression of MATH1, a marker of cerebellar granule cell progenitors, identifies different medulloblastoma sub-types. *Neuroscience Letters*, **2004**, 370, 180-5	3.3	45
33	Effects of thalidomide on parameters involved in angiogenesis: an in vitro study. *Journal of Neuro-Oncology*, **2003**, 64, 193-201	4.8	16

32	Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis. *International Journal of Cancer*, **2003**, 107, 493-7	7.5	51
31	Dexamethasone inhibits the anti-tumor effect of interleukin 4 on rat experimental gliomas. *Gene Therapy*, **2003**, 10, 188-92	4	34
30	The neural progenitor-restricted isoform of the MARK4 gene in 19q13.2 is upregulated in human gliomas and overexpressed in a subset of glioblastoma cell lines. *Oncogene*, **2003**, 22, 2581-91	9.2	57
29	Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. *Annals of Neurology*, **2002**, 52, 842-5	9.4	29
28	New insights into brain damage in stroke-prone rats: a nuclear magnetic imaging study. *Stroke*, **2002**, 33, 825-30	6.7	55
27	Utilizzo intraoperatorio delle immagini di spettroscopia RM nella chirurgia dei tumori cerebrali e correlazione con la neuropatologia. *The Neuroradiology Journal*, **2001**, 14, 9-12		
26	Intravascular lymphomatosis (IL) in a child mimicking a posterior fossa tumor. *Journal of Neuro-Oncology*, **2001**, 51, 47-50	4.8	12
25	High frequency of the H63D mutation of the hemochromatosis gene (HFE) in malignant gliomas. *Neurology*, **2001**, 57, 1342	6.5	20
24	Modulation of experimental allergic encephalomyelitis in Lewis rats by administration of a peptide of Fas ligand. *Journal of Autoimmunity*, **2001**, 17, 273-80	15.5	6
23	Gene therapy of experimental brain tumors using neural progenitor cells. *Nature Medicine*, **2000**, 6, 447-50	30.5	414
22	Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas. *Journal of Neuro-Oncology*, **2000**, 49, 71-5	4.8	9
21	Growth hormone and prolactin responses to corticotrophin-releasing-hormone in patients with Cushing© disease: a paracrine action of the adenomatous corticotrophic cells?. *Clinical Endocrinology*, **1998**, 49, 433-9	3.4	15
20	Meningo-cortical calcifying angiomatosis and celiac disease. *Clinical Neurology and Neurosurgery*, **1998**, 100, 209-15	2	8
19	IL-4 gene transfer for the treatment of experimental gliomas. *Advances in Experimental Medicine and Biology*, **1998**, 451, 315-21	3.6	6
18	Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. *Human Gene Therapy*, **1997**, 8, 1345-53	4.8	59
17	Gene transfer of suicide genes for the treatment of malignant gliomas: efficacy, limitations, and perspectives for a combined immunotherapy. *Acta Neurochirurgica Supplementum*, **1997**, 68, 100-4	1.7	2
16	The "bystander effect": association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. *Human Gene Therapy*, **1995**, 6, 763-72	4.8	123
15	Intracranial dissemination of pituitary adenoma. Case report and review of the literature. *Italian Journal of Neurological Sciences*, **1994**, 15, 195-200		9

14	Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin. *European Journal of Nuclear Medicine and Molecular Imaging*, **1994**, 21, 314		
13	Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin. *European Journal of Nuclear Medicine and Molecular Imaging*, **1994**, 21, 314-21		46
12	p53 mutations and microsatellite analysis of loss of heterozygosity in malignant gliomas. *Cancer Genetics and Cytogenetics*, **1994**, 74, 139-43		11
11	Increasing complexity of the karyotype in 50 human gliomas. Progressive evolution and de novo occurrence of cytogenetic alterations. *Cancer Genetics and Cytogenetics*, **1994**, 75, 77-89		45
10	Low frequency of NF1 gene mutations in malignant gliomas. *European Journal of Cancer*, **1993**, 29A, 1217-8	7.9	
9	Beta PP participates in PrP-amyloid plaques of Gerstmann-Sträussler-Scheinker disease, Indiana kindred. *Journal of Neuropathology and Experimental Neurology*, **1993**, 52, 64-70	3.1	41
8	Gliomatosis cerebri. Report of a case with isolated amnesic disorders. *Italian Journal of Neurological Sciences*, **1992**, 13, 503-6		12
7	Proliferating cell nuclear antigen expression in central nervous system neoplasms. *Virchows Archiv A, Pathological Anatomy and Histopathology*, **1991**, 419, 417-23		90
6	Histologic prognostic factors in ependymoma. *Childs Nervous System*, **1991**, 7, 177-82	1.7	122
5	Cytochrome c oxidase and coenzyme Q in neuromuscular diseases: a histochemical study. *Acta Neuropathologica*, **1990**, 81, 25-9	14.3	7
4	Alzheimer patients and Down patients: abnormal presynaptic terminals are related to cerebral preamyloid deposits. *Neuroscience Letters*, **1990**, 119, 56-9	3.3	49
3	Cerebral preamyloid deposits and congophilic angiopathy in aged dogs. *Neuroscience Letters*, **1990**, 114, 178-83	3.3	78
2	Sporadic distal myopathy with early adult onset: study of muscle biopsies and muscle cell cultures. *European Neurology*, **1989**, 29, 287-90	2.1	1
1	Free cytoplasmic Ca++ at rest and after cholinergic stimulus is increased in cultured muscle cells from Duchenne muscular dystrophy patients. *Neurology*, **1988**, 38, 476-80	6.5	78